Exploring the feasibility of introducing triple artemisinin-based combination therapy in the malaria treatment policy in Vietnam.
Drug resistance
Introduction strategies
Triple artemisinin-based combination therapy (TACT)
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
28 Oct 2023
28 Oct 2023
Historique:
received:
03
07
2023
accepted:
22
10
2023
medline:
30
10
2023
pubmed:
29
10
2023
entrez:
29
10
2023
Statut:
epublish
Résumé
This study investigates the processes regarding changing malaria treatment policies in Vietnam. Moreover, it explores the feasibility of introducing triple artemisinin-based combination therapy (TACT) in Vietnam to support the national malaria control and elimination plan. Data were collected via 12 in-depth interviews with key stakeholders, combined with a review of policy documents. TACT is considered as a useful backup strategy in case future treatment failures with current artemisinin-based combination therapy (ACT) would occur. Moreover, TACT is also considered as a promising strategy to prevent the re-establishment of malaria. However, regulatory procedures and implementation timelines for TACT were expected to be lengthy. Therefore, strategies to engage national decision-makers, regulators, and suppliers should be initiated soon, stipulating the benefits of TACT deployment. In Vietnam, a procedure to apply for an import permit without registration that has previously been applied to the introduction of artesunate-pyronaridine was proposed to accelerate the introduction of TACT. Global-level support through the World Health Organization recommendations and prequalification were considered critical for supporting the introduction of TACT in Vietnam. Appropriate approach strategies and early stakeholder engagement will be needed to accelerate the introduction of TACT in Vietnam.
Sections du résumé
BACKGROUND
BACKGROUND
This study investigates the processes regarding changing malaria treatment policies in Vietnam. Moreover, it explores the feasibility of introducing triple artemisinin-based combination therapy (TACT) in Vietnam to support the national malaria control and elimination plan.
METHODS
METHODS
Data were collected via 12 in-depth interviews with key stakeholders, combined with a review of policy documents.
RESULTS
RESULTS
TACT is considered as a useful backup strategy in case future treatment failures with current artemisinin-based combination therapy (ACT) would occur. Moreover, TACT is also considered as a promising strategy to prevent the re-establishment of malaria. However, regulatory procedures and implementation timelines for TACT were expected to be lengthy. Therefore, strategies to engage national decision-makers, regulators, and suppliers should be initiated soon, stipulating the benefits of TACT deployment. In Vietnam, a procedure to apply for an import permit without registration that has previously been applied to the introduction of artesunate-pyronaridine was proposed to accelerate the introduction of TACT. Global-level support through the World Health Organization recommendations and prequalification were considered critical for supporting the introduction of TACT in Vietnam.
CONCLUSIONS
CONCLUSIONS
Appropriate approach strategies and early stakeholder engagement will be needed to accelerate the introduction of TACT in Vietnam.
Identifiants
pubmed: 37898749
doi: 10.1186/s12936-023-04763-4
pii: 10.1186/s12936-023-04763-4
pmc: PMC10613363
doi:
Substances chimiques
Antimalarials
0
artemisinin
9RMU91N5K2
Artemisinins
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
326Informations de copyright
© 2023. The Author(s).
Références
Environ Innov Soc Transit. 2021 Sep;40:40-59
pubmed: 35106274
Clin Infect Dis. 2020 May 6;70(10):2187-2195
pubmed: 31251812
Emerg Infect Dis. 2017 Apr;23(4):715-717
pubmed: 28322709
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0027621
pubmed: 34570647
Antimicrob Agents Chemother. 2014 Dec;58(12):7049-55
pubmed: 25224002
Lancet Infect Dis. 2023 May;23(5):568-577
pubmed: 36462526
Trends Parasitol. 2021 Jan;37(1):15-24
pubmed: 33060063
Nat Commun. 2023 Jul 29;14(1):4568
pubmed: 37516752
Malar J. 2023 Sep 6;22(1):261
pubmed: 37674172
Malar J. 2022 Feb 22;21(1):61
pubmed: 35193586
J Infect Dis. 2008 Sep 15;198(6):911-9
pubmed: 18694333
Lancet Infect Dis. 2022 Jun;22(6):867-878
pubmed: 35276064
Antimicrob Agents Chemother. 2021 Mar 18;65(4):
pubmed: 33526483
Lancet. 2020 Apr 25;395(10233):1345-1360
pubmed: 32171078
Lancet. 2004 Jan 3;363(9402):18-22
pubmed: 14723988
Malar J. 2021 Apr 29;20(1):205
pubmed: 33926479